CompletedNot Applicable

Longevity Diet and the Fasting-mimicking Diet

Italy365 participantsStarted 2019-01-01

Plain-language summary

This retrospective clinical study examines the impact of the longevity diet and fasting-mimicking diet (FMD), either alone or combined, on body composition and health indicators. Focused on subjects from the Valter Longo Foundation (2019-2024), the study aims to evaluate their effects on body fat percentage, lean mass, muscle function, and lipid profiles. The longevity diet, rooted in centenarian dietary traditions, emphasizes isocaloric meals with a balance of complex carbohydrates, unsaturated fats, and plant-based proteins. FMD involves a 5-day highly hypocaloric vegan diet to simulate fasting benefits. Hypothesizing that a return to a modified Mediterranean diet or incorporating FMD could improve overall health, the study spans diverse cohorts based on intervention type, duration, obesity level, and physio-pathological status. Data, collected from electronic medical records, will undergo statistical analyses to compare pre- and post-intervention measurements, exploring outcomes across subgroups. Ethical considerations, including de-identified data and informed consent, ensure compliance with clinical research regulations. In conclusion, this study provides valuable insights into the potential health and longevity benefits of the longevity diet and FMD, with implications for public wellness.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy patients and/or those with diseases, excluding neoplastic and neurodegenerative pathologies; * Age \>/= 18 years; * Body mass index \>/= 18.5 kg/m2; * At least two visits, both characterized by bioimpedance and anthropometric analysis; * At least 3 months between the first and last bioimpedance and anthropometric analysis; * Signature of informed consent and privacy for the conducted visits. Exclusion Criteria: * Age \< 18 years; * Lack of informed consent or privacy; * Women who are pregnant or breastfeeding; * Patients affected by oncological and/or neurodegenerative pathologies.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Fat mass in %

Timeframe: Comparison of Fat mass in % at baseline and after a period between 3 months (minimum) and 2 years (maximum)

Trial details

NCT IDNCT07065955

SponsorFondazione Valter Longo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Overweight trials